Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, early stage

2995 - Surrogate endpoints for Overall Survival in Randomized Controlled Trials evaluating adjuvant treatment for breast cancer: a meta-analysis


09 Sep 2017


Breast cancer, early stage


Cytotoxic Therapy;  Breast Cancer


Marion Savina


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


M. Savina1, W. Jacot2, S. Mathoulin-Pélissier1, Y. Laghzali3, C. Bellera1, S. Gourgou3

Author affiliations

  • 1 Department Of Epidemiology And Clinical Research, Institut Bergonié Régional Cancer Institute of Bordeaux, 33000 - Bordeaux/FR
  • 2 Department Of Medical Oncology, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 3 Department Of Biostatistics, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR


Abstract 2995


In cancer randomized controlled trials (RCT), endpoints other than overall survival (OS) such as disease-free survival (DFS) are increasingly being used as primary endpoint. Their development is influenced by the need to reduce the number of patients, the duration and ultimately the cost of the trials. Their use as primary endpoint however require a rigorous validation as surrogate endpoints for OS. In adjuvant breast cancer, only a few studies evaluated surrogate endpoints for OS, limited by the use of aggregate data. We present the results of a meta-analysis of individual-patient data assessing surrogate endpoints for OS in the context of adjuvant breast cancer.


We evaluated four endpoints as potential surrogates for OS relying on a meta-analysis of 5 phase III trials: relapse-free survival (RFS), invasive DFS, locoregional RFS and distant DFS. At the patient level, we estimated the individual-level associations by jointly modeling each surrogate with OS using a copula function. At the trial level, we estimated the association between the treatment effects using (1) a linear regression model weighted by the trial size and (2) the two-step model proposed by Burzykowski, Molenbergh and Buyse.


We gathered individual-patient data from 11676 patients from 5 RCT. The endpoints were highly associated with OS at the patient level (r ≥ 0.98). At the trial level, invasive DFS showed the higher association with OS (R2WLR=0,78; R22SM=0,87).


This is the first meta-analysis on individual-patient data evaluating surrogate endpoints for OS in adjuvant breast cancer. These results suggest that the endpoints could be interesting candidate surrogates for OS, but further evaluation on a larger set of trials is required to improve the precision of our estimations of the trial-level associations.

Clinical trial identification

Legal entity responsible for the study

ICM Regional Cancer Center of Montpellier


French National Insitute of Cancer (INCa)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.